The WIZARD trial as a case study of flexible clinical trial design

Drug Information Journal

Volumn 40, Issue 3, 2006, Pages 345-353

  Cook, Thomas D ^a   Benner, Rebecca J ^b   Fisher, Marian R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Adaptive design; Composite end points; Conditional power; Event driven trials; Group sequential testing

Indexed keywords

AZITHROMYCIN;

ATHEROSCLEROSIS; CASE STUDY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ECONOMIC ASPECT; HUMAN; METHODOLOGY; PRIORITY JOURNAL; QUALITY CONTROL; RESEARCH ETHICS; REVIEW; SAMPLE SIZE; VALIDITY;

EID: 33747608207     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150604000313     Document Type: Review

References (24)

1. Dunne MW. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD ([Weekly Intervention with Zithromax Azithromycin] for Atherosclerosis and Its Related Disorders) trial. J Infect Dis. 2000;181(suppl 3):S572-S578.
2. O'Connor CM, Dunne MW, Pfeffer MA, et al. A double-blind, randomized, placebo controlled trial of azithromycin for the secondary prevention of coronary heart disease: the WIZARD trial. JAMA. 2003;290:1459-1466.
3. EaSt-2000: Software for the Design and interim Monitoring of Group Sequential Clinical Trials. Cambridge, MA: Cytel Software Corporation; 2000.
4. O'Brien P, Fleming T. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
5. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983; 70:659-663.
6. Lan KKG, Wittes J. The B-value: a tool for monitoring data. Biometrics. 1988;44:579-585.
7. Tsiatis AA. The asymptotic joint distribution of the efficient scores test for the proportional hazards model calculated over time. Biometrika. 1981;68:311-315.
8. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics. 1994;50: 1029-1041.
9. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics. 1999;55:1286-1290.
10. Müller HH, Schäfer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. Biometrics. 2001;57:886-891.
11. Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics. 1995;51:1315-1324.
12. Lan KKG, Trost DC. Estimation of parameters and sample size re-estimation. In: ASA Proceedings of the Biopharmaceutical Section. Alexandria, VA: American Statistical Association; 1997:48-51.
13. Fisher LD. Self-designing clinical trials. Stat Med. 1998;17:1551-1562.
14. Shen Y, Fisher L. Statistical inference for self-designing clinical trials with a one-sided hypothesis. Biometrics. 1999;55:190-197.
15. Cui L, Hung HMJ, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics. 1999;55:853-857.
16. Li G, Shih WJ, Xie T, Lu J. A sample size adjustment procedure for clinical trials based on conditional power. Biostatistics. 2002;3:277-287.
17. Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials (with comments). Stat Med. 1990;9:65-72.
18. Gould AL, Shih WJ. Modifying the design of ongoing trials without unblinding. Stat Med. 1998;17:89-100.
19. Friede T, Kieser M. Sample size recalculation for binary data in internal pilot study designs. Pharm Stat. 2004;3:269-279.
20. Cook TD. Methods for mid-course corrections in clinical trials with survival outcomes. Stat Med. 2003;22:3431-3447.
21. Lakatos E. Sample size determination in clinical trials with time-dependent rates of losses and noncompliance. Controlled Clin Trials. 1986;7: 189-199.
22. Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics. 1988;44:229-241.
23. Armitage P, McPherson C, Rowe B. Repeated significance tests on accumulating data. J R Stat Soc Ser A. 1969;132:235-244.
24. Reboussin DM, DeMets DL, Kim K, Lan KKG. Computations for group sequential boundaries using the Lan-DeMets spending function method. Controlled Clin Trials. 2000;21:190-207.